Rohit Goyal, MD
Critical Care Medicine · Fredericksburg, VANPI 1881879724
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,351 of the $95,201 with a category attached, or 65.5%. Pulmonx Corporation accounts for 66.7% of it on its own, with 52 other manufacturers making up the rest. Reporting peaked in 2023 at $55,332 and has fallen 83.0% since, to $9,432 in 2025. Among critical care medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 694 payments — averaging $137.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$63K
- Intuitive Surgical$8K
- United Therapeutics Corporation$7K
- AstraZeneca$2K
- Johnson & Johnson$2K
- GSK$2K
- plus $11K from 47 others
What the payments were for
- Consulting fees$62,35165%
- Travel & lodging$11,31412%
- Food & beverage$16,44017%
- Education$5,0835%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$63,053
- CHARTIS CATHETER$52,328
- ZEPHYR DELIVERY CATHETER$52,328
- PULMONX CHARTIS TABLET CONSOLE$52,328
- Da Vinci Surgical System$8,182
- Monarch Platform$1,637
- SINGLE USE SUCTION VALVE (Sterile)$875
- Olympus$397
- TEZSPIRE$357
- ZEPBOUND$247
- AIRSUPRA$125
- BREZTRI$125
- FASENRA$125
- SYMBICORT$125
- Pulmonx Endobronchial Valve EBV$125
- NUCALA$120
- ViziShot 2 FLEX$117
How this compares
$95,201 in reported general payments places this provider in the 95th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $223,018 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 22 | $178,588 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 177 | $177,493 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $104,008 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $60,407 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $41,365 |
| Spiriva RespimatTiotropium Bromide | 27 | $26,816 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $25,130 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $15,538 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $10,676 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $9,368 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 198 | $5,707 |
| Wixela InhubFluticasone Propion/Salmeterol | 26 | $4,625 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $3,894 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $2,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,053 | $265,37368 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,630 | $243,988293 claims |
| Grifols USA, LLCProlastin C | $223 | $178,58822 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $783 | $104,00812 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,051 | $71,08393 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Fredericksburg
- Erik OsbornFredericksburg$17K
- Ali HafizFredericksburg$16K
- Lauren RileyFredericksburg$713
- Oksana ShlobinFalls Church$375K
- Matthew WilliamsAnnandale$235K
- Sami Abdul JawadFalls Church$193K
- Rajiv MalhotraRichmond$187K
- Thomas BouderWinchester$163K
- Christopher KingFalls Church$131K
- Robert ThieleCharlottesville$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.